Liver transplant patients get new hope: CertiroBell vs standard drug
NCT ID NCT04471441
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether CertiroBell (everolimus) works better than mycophenolate mofetil at preventing organ rejection, graft loss, or death in 150 adults who received a liver transplant from a living donor. Participants took one of the two drugs for up to a year. The goal was to see which drug keeps the new liver healthier with fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Everolimus (CertiroBell tablet)
- What this could lead to
- If successful, this could offer a safer or more effective way to prevent organ rejection after liver transplant, reducing the need for lifelong anti-rejection drugs.
- What could go wrong
- This is a completed Phase 4 trial with 150 participants, so results are available but may not apply to all transplant patients. Everolimus can cause side effects like infections or mouth sores.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Severance Hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can personalized antibiotics outsmart resistant bacteria in liver transplants?
- Blood-Clotting showdown: which device best guides bleeding care in High-Risk patients?
- Could a daily pill shield transplant patients from a common virus?
- Which liver biopsy needle delivers the best tissue? a Head-to-Head comparison
- Transplant breakdown? new study checks organ fluid for hidden germs
- New study aims to catch transplant complications early with blood and urine tests